Skip to content
10-Q

Quarterly Report

CRISPR Therapeutics AG CRSP

0000950170-25-064468

← back to feed
Filed
May 6, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 2, 2025 86.36M sh
Current Liabilities Q1 2025 · Mar 31, 2025 $119.45M
Current Liabilities Q1 2025 · Dec 31, 2024 $87.78M
Total Liabilities Q1 2025 · Mar 31, 2025 $336.94M
Total Liabilities Q1 2025 · Dec 31, 2024 $309.95M
Current Assets Q1 2025 · Mar 31, 2025 $1.87B
Current Assets Q1 2025 · Dec 31, 2024 $1.94B
Total Assets Q1 2025 · Mar 31, 2025 $2.17B
Total Assets Q1 2025 · Dec 31, 2024 $2.24B
Cash And Equivalents Q1 2025 · Dec 31, 2024 $298.26M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $707.43M
Shares Diluted Q1 2025 · Mar 31, 2024 81.79M sh
Capex Q1 2025 · Mar 31, 2024 $721K
Operating Cash Flow Q1 2025 · Mar 31, 2024 $109.75M
Stockholders Equity Q1 2025 · Mar 31, 2024 $2.08B
Stockholders Equity Q1 2025 · Dec 31, 2023 $1.88B
Eps Diluted Q1 2025 · Mar 31, 2024 −$1.43
Eps Basic Q1 2025 · Mar 31, 2024 −$1.43
Sga Expense Q1 2025 · Mar 31, 2024 $17.95M
Rd Expense Q1 2025 · Mar 31, 2024 $76.17M
Net Income Q1 2025 · Mar 31, 2024 −$116.59M
Operating Income Q1 2025 · Mar 31, 2024 −$140.59M
Revenue Q1 2025 · Mar 31, 2024 $504K